2022 annual financial data
Protara Therapeutics 2022 Operating cash flow growth
Direct answer
Operating cash flow growth was 23.32%.
Operating income was -67,062,000 USD and net income was -65,952,000 USD.
Operating cash flow was -26,457,000 USD.
Get free Protara Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -67,062,000 USD
- Net income
- -65,952,000 USD
- Operating cash flow
- -26,457,000 USD